Skip to search formSkip to main contentSkip to account menu

Intravenous bisphosphonates

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Effect of renal impairment (RI) on intravenous bisphosphonates (IVBP) and multiple myeloma (MM) treatment.
e20007Background: RI is prevalent in MM patients and associated with poor survival and increased costs. IVBPs are recommended to… 
2013
2013
Utilization of intravenous bisphosphonates (IVBs) in patients with bone metastases (BMets) secondary to breast, lung, or prostate cancer (BC, LC, PC).
e20665 Background: Cancer patients with BMets are predisposed to skeletal complications. Bone targeted therapies such as… 
Review
2013
Review
2013
Trends in use of intravenous bisphosphonates in patients with prostate cancer and newly diagnosed metastases to bone in two large U.S. integrated health systems.
192 Background: Bone is a common site of metastatic involvement in patients (pts) with prostate cancer (PC). Bony metastases… 
2011
2011
Bone scans, bisphosphonates, and a lack of acute changes within the mandible.
Review
2011
Review
2011
Denosumab as Bone Modifying Therapy in Solid Tumors
For many solid tumors, bone is a common site of spread and one that compromises the quality of life of patients. The routine use… 
Review
2010
Review
2010
Efficacy and safety of intravenous bisphosphonates beyond two years of use.
e19619 Background: Metastatic bone disease is a common complication of several malignancies, including breast cancer, prostate… 
2009
2009
Long-term treatment with intravenous bisphosphonates in metastatic breast cancer (MBC).
1035 Background: Intravenous bisphosphonates (IV BPs) are safe and effective in reducing skeletal related events in MBC. The… 
Review
2009
Review
2009
Efficacy and safety of intravenous bisphosphonates beyond two years
Background: Metastatic bone disease, a common complication of malignancy, causes significant morbidity in affected patients… 
2009
2009
Risk of acute renal failure among breast cancer patients and chemotherapy treatment of breast cancer patients with a history of renal insufficiency in a commercially-insured population in the United…
e22104 Background: Risk of acute renal failure (ARF) among breast cancer (BC) patients may increase with nephrotoxic chemotherapy… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)